A consultant pharmacist, during a monthly drug regimen review, identifies that a resident is prescribed two medications with a known significant drug-to-drug interaction that could cause serious harm. According to 42 CFR §483.45, what is the pharmacist's required action after identifying this irregularity?
-
A
Document the finding for review at the next quarterly Quality Assurance meeting.
-
B
Contact the resident's family to inform them of the potential risk.
-
C
Report the finding to the facility's administrator and medical director.
-
D
Report the irregularity to the attending physician and the director of nursing.